Purple Biotech (PPBT) Common Equity (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Common Equity of $9.7 million for Q1 2026, down 70.44% year-over-year from $32.7 million in Q1 2025, and little changed quarter-over-quarter from $9.7 million in Q4 2025.
Purple Biotech (PPBT) Common Equity (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Common Equity for 13 consecutive years, with $9.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 70.44% year-over-year to $9.7 million; the TTM figure through Mar 2026 stood at $9.7 million (down 70.44% YoY), while the FY2025 annual figure was $9.7 million, down 70.65% from the prior year.
- Common Equity steadied at $9.7 million in Q1 2026 per PPBT's latest filing, from $9.7 million in the prior quarter.
- Across five years, Common Equity topped out at $58.3 million in Q1 2022 and bottomed at $9.7 million in Q4 2025.
- Historically, Common Equity has averaged $36.2 million across 5 years, with a median of $32.9 million in 2024.
- On a YoY basis, Common Equity climbed as much as 11.36% in 2025 and fell as far as 70.65% in 2025.
- Purple Biotech's Common Equity stood at $47.1 million in 2022, then decreased by 27.18% to $34.3 million in 2023, then fell by 4.04% to $32.9 million in 2024, then slumped by 70.65% to $9.7 million in 2025, then climbed by 0.05% to $9.7 million in 2026.
- Business Quant data shows PPBT's Common Equity at $9.7 million in Q1 2026, $9.7 million in Q4 2025, and $32.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 9.79 Bn |
| 10 | Purple Biotech | 127.07 | 127.07 | - | 12.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.66 Mn |
| Dec 31, 2025 | 9.66 Mn |
| Sep 30, 2025 | 32.82 Mn |
| Jun 30, 2025 | 32.05 Mn |
| Mar 31, 2025 | 32.70 Mn |
| Dec 31, 2024 | 32.91 Mn |
| Sep 30, 2024 | 29.47 Mn |
| Jun 30, 2024 | 29.38 Mn |
| Mar 31, 2024 | 31.09 Mn |
| Dec 31, 2023 | 34.30 Mn |
| Sep 30, 2023 | 38.72 Mn |
| Jun 30, 2023 | 42.75 Mn |
| Mar 31, 2023 | 47.05 Mn |
| Dec 31, 2022 | 47.10 Mn |
| Sep 30, 2022 | 52.11 Mn |
| Jun 30, 2022 | 55.66 Mn |
| Mar 31, 2022 | 58.32 Mn |
| Dec 31, 2021 | 65.11 Mn |
| Sep 30, 2021 | 69.37 Mn |
| Jun 30, 2021 | 72.12 Mn |